XTL BIOPHARMACEUTICALS LTD. (XTLB)

Every figure this model derived for XTLB, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 54,000 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2024-12-31
cash 3,750,000 CashAndCashEquivalents 2024-12-31
current assets 1,340,000 CurrentAssets 2024-12-31
current liabilities 2,207,000 CurrentLiabilities 2024-12-31
equity 5,435,000 Equity 2024-12-31
interest expense 28,000 InterestExpense 2024-12-31
ocf -1,618,000 CashFlowsFromUsedInOperatingActivities 2024-12-31
revenue 451,000 Revenue 2024-12-31
sbc 264,000 AdjustmentsForSharebasedPayments 2024-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up XTLB on one particular measure came for.

RatioValue
cash operating margin-378.94
current ratio0.61
current ratio reported0.61
dilution pct29.16
fcf margin-370.73
interest cover-77.57
operating margin-481.6
owner earnings margin-429.27
roic-87.5
sbc pct revenue58.54

What to be careful about

What this model itself distrusts about XTLB's figures. Written by the derivation as it ran, not added afterwards.